Controlled-release carvedilol in the management of systemic hypertension and myocardial dysfunction

References

• Al-HesayenAAzevedoERFlorasJS2005Selective versus non-selective beta-adrenergic receptor blockade in chronic heart failure: differential effects on myocardial energy substrate utilizationEur J Heart Fail76182315921803
   PubMed Web of Science ®Google Scholar
• American Heart Association2007Heart Disease and Stroke Statistics – 2007 UpdateDallas, TexasAmerican Heart Association
   Google Scholar
• AugustP2003Initial treatment of hypertensionN Engl J Med348610712584370
   PubMed Web of Science ®Google Scholar
• Australia/New Zealand Heart Failure Research Collaborative Group1997Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative GroupLancet349375809033462
   PubMed Web of Science ®Google Scholar
• BairdMGBentley-TaylorMMCarruthersSG1984A study of efficacy, tolerance and compliance of once-daily versus twice-daily metoprolol (Betaloc) in hypertension. Betaloc Compliance Canadian Cooperative Study GroupClin Invest Med7951026380858
   PubMed Web of Science ®Google Scholar
• BakrisGLFonsecaVKatholiRE2004Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trialJAMA29222273615536109
   PubMed Web of Science ®Google Scholar
• BakrisGLHartPRitzE2006aBeta blockers in the management of chronic kidney diseaseKidney Int7019051317021610
   PubMed Web of Science ®Google Scholar
• BakrisGLTarkaEAWaterhouseB2006bCardiovascular risk factors in hypertension: rationale and design of studies to investigate the effects of controlled-release carvedilol on regression of left ventricular hypertrophy and lipid profileAm J Cardiol9846L52L
   PubMed Web of Science ®Google Scholar
• BangaloreSKamalakkannanGParkarS2007aFixed-dose combinations improve medication compliance: a meta-analysisAm J Med120713917679131
   PubMed Web of Science ®Google Scholar
• BangaloreSMesserliFHKostisJB2007bCardiovascular protection using beta-blockers: a critical review of the evidenceJ Am Coll Cardiol505637217692739
   PubMed Web of Science ®Google Scholar
• BasatOUcakSSeberS2006After myocardial infarction carvedilol improves insulin resistance compared to metoprololClin Res Cardiol959910416598518
   PubMedGoogle Scholar
• CarterNJKeatingGM2008Controlled-release carvedilolAm J Cardiovasc Drugs82718218690761
   PubMed Web of Science ®Google Scholar
• ChobanianAVBakrisGLBlackHR2003Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureHypertension4212065214656957
   PubMed Web of Science ®Google Scholar
• ClaxtonAJCramerJPierceC2001A systematic review of the associations between dose regimens and medication complianceClin Ther23129631011558866
   PubMed Web of Science ®Google Scholar
• ClelandJGCharlesworthALubsenJ2006A comparison of the effects of carvedilol and metoprolol on well-being, morbidity, and mortality (the “patient journey”) in patients with heart failure: a report from the Carvedilol Or Metoprolol European Trial (COMET)J Am Coll Cardiol4716031116630997
   PubMed Web of Science ®Google Scholar
• ColagiuriSCullCAHolmanRR2002Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes? UK prospective diabetes study 61Diabetes Care251410712145243
   PubMed Web of Science ®Google Scholar
• CushmanWCFordCECutlerJA2002Success and predictors of blood pressure control in diverse North American settings: the anti-hypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)J Clin Hypertens (Greenwich)439340412461301
   PubMedGoogle Scholar
• DandonaPGhanimHBrooksDP2007Antioxidant activity of carvedilol in cardiovascular diseaseJ Hypertens257314117351362
   PubMed Web of Science ®Google Scholar
• DargieHJ2001Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trialLancet35713859011356434
   PubMed Web of Science ®Google Scholar
• DoughtyRNWhalleyGAWalshHA2004Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: the CAPRICORN Echo SubstudyCirculation109201614707020
   PubMed Web of Science ®Google Scholar
• EganBMBasileJChiltonRJ2005Cardioprotection: the role of beta-blocker therapyJ Clin Hypertens (Greenwich)74091616015051
   PubMedGoogle Scholar
• FonarowGC2004Managing the patient with diabetes mellitus and heart failure: issues and considerationsAm J Med116Suppl 5A76S88S15019865
   PubMedGoogle Scholar
• FonarowGC2006Profile of carvedilol controlled-release: a new once-daily formulation of carvedilolExpert Opin Pharmacother725334617150007
   PubMed Web of Science ®Google Scholar
• FonarowGCLukasMARobertsonM2007Effects of carvedilol early after myocardial infarction: analysis of the first 30 days in Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN)Am Heart J1546374417892984
   PubMed Web of Science ®Google Scholar
• FrishmanWH1998CarvedilolN Engl J Med3391759659845712
   PubMed Web of Science ®Google Scholar
• FrishmanWH2003Alpha- and beta-adrenergic blocking drugsFrishmanWHSonnenblickEHSicaDACardiovascular pharmacotherapeutics2nd edNew YorkMcGraw Hill6797
   Google Scholar
• FrishmanWH2007aA historical perspective on the development of beta-adrenergic blockersJ Clin Hypertens94 Suppl 31927
   PubMedGoogle Scholar
• FrishmanWH2007bImportance of medication adherence in cardiovascular disease and the value of once-daily treatment regimensCardiol Rev152576317700384
   PubMedGoogle Scholar
• GiuglianoDAcamporaRMarfellaR1997Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trialAnn Intern Med12695599182472
   PubMed Web of Science ®Google Scholar
• GoldhammerEMaorIShnitzerS2007The early anti-oxidant effect of carvedilol predicts the clinical course in congestive heart failure patientsJ Cardiovasc Med (Hagerstown)8453617502762
   PubMed Web of Science ®Google Scholar
• GreenbergBHMehraMTeerlinkJR2006COMPARE: comparison of the effects of carvedilol CR and carvedilol IR on left ventricular ejection fraction in patients with heart failureAm J Cardiol9853L9L
   PubMed Web of Science ®Google Scholar
• HauptmanPJPresslerSJSackner-BernsteinJ2006Rationale and design of CASPER: compliance and quality of life study comparing once-daily carvedilol CR and twice-daily carvedilol IR in patients with heart failureAm J Cardiol9860L6L16784921
   PubMed Web of Science ®Google Scholar
• HendersonLSTeneroDMBaidooCA2006Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertensionAm J Cardiol9817L26L
   PubMed Web of Science ®Google Scholar
• HendersonLSTeneroDMCampanileAM2007Ethanol does not alter the pharmacokinetic profile of the controlled-release formulation of carvedilolJ Clin Pharmacol4713586517962424
   PubMed Web of Science ®Google Scholar
• JacobSRettKWicklmayrM1996Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol studyJ Hypertens14489948761899
   PubMed Web of Science ®Google Scholar
• JohnsonMLPietzKBattlemanDS2004Prevalence of comorbid hypertension and dyslipidemia and associated cardiovascular diseaseAm J Manag Care109263215617368
   PubMed Web of Science ®Google Scholar
• KozlovskiVILomnickaMChlopickiS2006Nebivovol and carvedilol induce NO-dependent coronary vasodilatation that is unlikely to be mediated by extracellular ATP in the isolated guinea pig heartPharmacol Rep58Suppl1031017332679
   PubMedGoogle Scholar
• KurumTTatliEYukselM2007Effects of carvedilol on plasma levels of pro-inflammatory cytokines in patients with ischemic and nonischemic dilated cardiomyopathyTex Heart Inst J3452917420794
   PubMed Web of Science ®Google Scholar
• LefkowitzRJRajagopalKWhalenEJ2006New roles for beta-arrestins in cell signaling: not just for seven-transmembrane receptorsMol Cell246435217157248
   PubMed Web of Science ®Google Scholar
• LeventhalMJRiegelBCarlsonB2005Negotiating compliance in heart failure: remaining issues and questionsEur J Cardiovasc Nurs429830715893959
   PubMedGoogle Scholar
• LindholmLHCarlbergBSamuelssonO2005Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysisLancet36615455316257341
   PubMed Web of Science ®Google Scholar
• MaackCCremersBFleschM2000Different intrinsic activities of bucindolol, carvedilol and metoprolol in human failing myocardiumBr J Pharmacol1301131910882399
   PubMed Web of Science ®Google Scholar
• MaggiEMarchesiECoviniD1996Protective effects of carvedilol, a vasodilating beta-adrenoceptor blocker, against in vivo low density lipoprotein oxidation in essential hypertensionJ Cardiovasc Pharmacol2753288847870
   PubMed Web of Science ®Google Scholar
• ManleyS2003Haemoglobin A1c – a marker for complications of type 2 diabetes: the experience from the UK Prospective Diabetes Study (UKPDS)Clin Chem Lab Med4111829014598868
   PubMed Web of Science ®Google Scholar
• McGillJBBakrisGLFonsecaV2007beta-Blocker use and diabetes symptom score: results from the GEMINI studyDiabetes Obes Metab94081717391169
   PubMed Web of Science ®Google Scholar
• McMurrayJKoberLRobertsonM2005Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trialJ Am Coll Cardiol455253015708698
   PubMed Web of Science ®Google Scholar
• MesserliFHGrossmanE2004beta-Blockers in hypertension: is carvedilol different?Am J Cardiol937B12B
   PubMed Web of Science ®Google Scholar
• MetraMGiubbiniRNodariS2000Differential effects of beta-blockers in patients with heart failure: A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilolCirculation1025465110920067
   PubMed Web of Science ®Google Scholar
• MorenoAJSantosDJPalmeiraCM1998Ischemic heart disease: the role of mitochondria – carvedilol prevents lipid peroxidation of mitochondrial membranesRev Port Cardiol17Suppl 2II63779835783
   PubMedGoogle Scholar
• NakamuraKKusanoKNakamuraY2002Carvedilol decreases elevated oxidative stress in human failing myocardiumCirculation10528677112070115
   PubMed Web of Science ®Google Scholar
• NicholsAJSulpizioACAshtonDJ1989The interaction of the enantiomers of carvedilol with alpha 1- and beta 1-adrenoceptorsChirality1265702577144
   PubMed Web of Science ®Google Scholar
• OthmanAATeneroDMBoyleDA2007Population pharmacokinetics of S(−)-carvedilol in healthy volunteers after administration of the immediate-release (IR) and the new controlled-release (CR) dosage forms of the racemateAaps J9E2081817614362
   PubMed Web of Science ®Google Scholar
• OtterstadJEFordI2002The effect of carvedilol in patients with impaired left ventricular systolic function following an acute myocardial infarction. How do the treatment effects on total mortality and recurrent myocardial infarction in CAPRICORN compare with previous beta-blocker trials?Eur J Heart Fail4501612167391
   PubMed Web of Science ®Google Scholar
• PackerMBristowMRCohnJN1996The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study GroupN Engl J Med3341349558614419
   PubMed Web of Science ®Google Scholar
• PackerM1998Beta-adrenergic blockade in chronic heart failure: principles, progress, and practiceProg Cardiovasc Dis4139529715822
   PubMed Web of Science ®Google Scholar
• PackerMFowlerMBRoeckerEB2002Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) studyCirculation1062194912390947
   PubMed Web of Science ®Google Scholar
• PackerMLukasMATeneroDM2006Pharmacokinetic profile of controlled-release carvedilol in patients with left ventricular dysfunction associated with chronic heart failure or after myocardial infarctionAm J Cardiol9839L45L
   PubMed Web of Science ®Google Scholar
• PadiSSChopraK2002Salvage of cyclosporine A-induced oxidative stress and renal dysfunction by carvedilolNephron926859212372956
   PubMed Web of Science ®Google Scholar
• PatelPATilleyDGRockmanHA2008Beta-Arrestin-Mediated Signaling in the HeartCirc J721725918838825
   PubMed Web of Science ®Google Scholar
• PedersenMECockcroftJR2007The vasodilatory beta-blockersCurr Hypertens Rep92697717686376
   PubMed Web of Science ®Google Scholar
• PodbregarMVogaG2002Effect of selective and nonselective beta-blockers on resting energy production rate and total body substrate utilization in chronic heart failureJ Card Fail83697812528088
   PubMed Web of Science ®Google Scholar
• Poole-WilsonPASwedbergKClelandJG2003Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trialLancet36271312853193
   PubMed Web of Science ®Google Scholar
• RaoRBGoldfrankLR1998Fixed-dose combination therapy: panacea or poison?Intensive Care Med2428359609404
   PubMed Web of Science ®Google Scholar
• RasmussenJNGislasonGHRasmussenS2007Use of statins and beta-blockers after acute myocardial infarction according to income and educationJ Epidemiol Community Health611091718000133
   PubMed Web of Science ®Google Scholar
• RosamondWFlegalKFurieK2008Heart disease and stroke statistics – 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics SubcommitteeCirculation117e2514618086926
   PubMed Web of Science ®Google Scholar
• StamlerJWentworthDNeatonJD1986Prevalence and prognostic significance of hypercholesterolemia in men with hypertension. Prospective data on the primary screenees of the Multiple Risk Factor Intervention TrialAm J Med803393946459
   PubMed Web of Science ®Google Scholar
• StanleyWCRecchiaFALopaschukGD2005Myocardial substrate metabolism in the normal and failing heartPhysiol Rev85109312915987803
   PubMed Web of Science ®Google Scholar
• SundbergSTiihonenKGordinA1987Vasodilatory effects of carvedilol and pindololJ Cardiovasc Pharmacol10Suppl 11S76802454373
   PubMedGoogle Scholar
• TatliEKurumT2005A controlled study of the effects of carvedilol on clinical events, left ventricular function and proinflammatory cytokines levels in patients with dilated cardiomyopathyCan J Cardiol21344815838561
   PubMed Web of Science ®Google Scholar
• TeneroDMHendersonLSBaidooCA2006Pharmacokinetic properties of a new controlled-release formulation of carvedilolAm J Cardiol985L16L
   PubMed Web of Science ®Google Scholar
• TodaN2003Vasodilating beta-adrenoceptor blockers as cardiovascular therapeuticsPharmacol Ther1002153414652111
   PubMed Web of Science ®Google Scholar
• Torp-PedersenCPoole-WilsonPASwedbergK2005Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure – COMETAm Heart J149370615846279
   PubMed Web of Science ®Google Scholar
• Torp-PedersenCMetraMCharlesworthA2007Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET)Heart939687317237130
   PubMed Web of Science ®Google Scholar
• UdelsonJEPresslerSJSackner-BernsteinJ2007Compliance with Once Daily Controlled Release vs Twice Daily Immediate Release Carvedilol in Patients with Heart Failure: The CASPER TrialJ Card Fail13S135
   Google Scholar
• VittorioTJZoltyRKasperME2008Differential effects of carvedilol and metoprolol succinate on plasma norepinephrine release and peak exercise heart rate in subjects with chronic heart failureJ Cardiovasc Pharmacol Ther1351718287590
   PubMed Web of Science ®Google Scholar
• WallhausTRTaylorMDeGradoTR2001Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failureCirculation1032441611369683
   PubMed Web of Science ®Google Scholar
• WeberMABakrisGLTarkaEA2006aEfficacy of a once-daily formulation of carvedilol for the treatment of hypertensionJ Clin Hypertens (Greenwich)8840917170609
   PubMedGoogle Scholar
• WeberMASicaDATarkaEA2006bControlled-release carvedilol in the treatment of essential hypertensionAm J Cardiol9832L8L
   PubMed Web of Science ®Google Scholar
• WislerJWDeWireSMWhalenEJ2007A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signalingProc Natl Acad Sci U S A104166576217925438
   PubMed Web of Science ®Google Scholar
• World Health Organization2007Cardiovascular diseases Fact sheet no. 317 [online]. Accessed August 4, 2008. URL: http://www.who.int/mediacentre/factsheets/fs317/en/index.html.
   Google Scholar
• WrightJTJrBakrisGLBellDS2007Lowering blood pressure with beta-blockers in combination with other renin-angiotensin system blockers in patients with hypertension and type 2 diabetes: results from the GEMINI TrialJ Clin Hypertens (Greenwich)9842917978591
   PubMedGoogle Scholar
• YangSPHoLJChengSM2004Carvedilol differentially regulates cytokine production from activated human peripheral blood mononuclear cellsCardiovasc Drugs Ther18183815229385
   PubMed Web of Science ®Google Scholar